Aug 2026· Psychopharmacology· 0 citations· 66 references
Medicine
TL;DR
New mechanistic truths of how m6A-dependent RNA regulation contributes to the progression of AD are compiled and therapeutic opportunities of METTL3/IGF2BP2 axis targeting for novel RNA-based therapies for neurodegenerative disease are discussed.
High mobility group box 1 (HMGB1) is a crucial modulator of neuroinflammation in AD, according to new research, and a viable treatment approach for reducing neuroinflammation and associated pathologies with AD is to target HMGB1-mediated signalling networks.
Prashant Tyagi, Sneha Kumari, Prajjwal Sharma et al.· International Immunopharmaco...· 1 citation
This review aims to compile recent markers of aging and Alzheimer's disease in immune, glial, and neuronal cells, which are increasingly vital for enhancing diagnostic precision and monitoring disease progression.
Ejiofor J. Alobu, O. Uchewa, A. Ibegbu· IBRO Neuroscience Reports· 0 citations
It is proposed that RIPK1 is an understudied pathway in Alzheimer’s disease pathogenesis and that defining its cell-type-specific and stage-dependent functions will be essential to determine whether RIPK1 inhibition can be developed as a disease-modifying therapeutic strategy.
Antonella Caccamo, M. Lanza, G. Casili et al.· Cells· 0 citations
How dynamic changes in IRE1α signaling bias contribute to amyloidogenic progression in AD is examined and whether selective modulation of adaptive versus maladaptive IRE1α outputs may offer stage-dependent therapeutic benefit is considered.
Dan-Yun Wang, Qinan Yin· Frontiers in Molecular Biosc...· 0 citations
Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to transla...
